Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 40 points (-0.2%) at 17,811 as of Thursday, May 26, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,440 issues advancing vs. 1,460 declining with 179 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.0%. On the negative front, top decliners within the industry include

Incyte

(

INCY

), down 1.8%, and

Gilead

(

GILD

), down 1.5%. Top gainers within the industry include

Biogen

(

BIIB

), up 1.2%,

Eli Lilly and

(

LLY

), up 0.9% and

AbbVie

(

ABBV

), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Ionis Pharmaceuticals

(

IONS

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Ionis Pharmaceuticals is down $13.76 (-39.0%) to $21.50 on heavy volume. Thus far, 16.9 million shares of Ionis Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $21.35-$26.81 after having opened the day at $26.81 as compared to the previous trading day's close of $35.26.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, develops drugs for patients with severe and rare diseases in the United States. Ionis Pharmaceuticals has a market cap of $4.0 billion and is part of the health care sector. Shares are down 43.1% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts that rate Ionis Pharmaceuticals a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Ionis Pharmaceuticals

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full

Ionis Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Novo Nordisk A/S

(

NVO

) is down $0.49 (-0.9%) to $55.81 on heavy volume. Thus far, 1.0 million shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $55.79-$56.13 after having opened the day at $55.94 as compared to the previous trading day's close of $56.30.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $142.9 billion and is part of the health care sector. Shares are down 3.1% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Novo Nordisk A/S

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Novo Nordisk A/S Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Shire

(

SHPG

) is down $2.10 (-1.1%) to $189.68 on heavy volume. Thus far, 2.5 million shares of Shire exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $189.42-$193.35 after having opened the day at $192.56 as compared to the previous trading day's close of $191.78.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Shire plc, a biotech company, together with its subsidiaries, engages in the research, development, licensing, manufacture, marketing, distribution, and sale of medicines for patients with rare diseases and other select conditions. Shire has a market cap of $37.1 billion and is part of the health care sector. Shares are down 6.5% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Shire a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Shire

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Shire Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).